Ligand Pharmaceuticals LGND Tolerance Therapeutics (Tzield®) — Gross carrying value

Other product segments

Qarziba

$103.72M—

Similar metrics at other companies

CRBGDeferred Tax Assets, Net before Valuation Allowance

$7.82B-13.6%

AMEGross Carrying Amount

$5.13B+9.4%

DUKDeferred Tax Liabilities, Gross

$15.82B+0.9%

EBAYDeferred Tax Liabilities, Gross

$2.25B+0.9%

WMBDeferred Tax Liabilities, Gross

$6.43B+18.4%

GDGross Carrying Amount

$3.94B+1.0%

Other financials

Income statement

See full

Revenue$51.7M+14.1%

Operating income$17.4M+148%

Net income-$13.3M+68.6%

EPS (diluted)-$0.67+69.7%

Balance sheet

See full

Cash & equivalents$115.1M+140%

Total debt$5.1M+14.2%

Total equity$997.3M+25.4%

Total assets$1.5B+69.2%

Cash flow

See full

Operating cash flow$48.7M+291%

CapEx$228.0K+6.5%

Free cash flow$48.5M+289%

Valuation

See full

Market cap$5.51B+96.7%

Enterprise value$5.4B+95.4%

P/E35.9×—

P/S20.1×+4.6×

Profitability

See full

Gross margin91.9%—

Operating margin34.5%+23.0pp

Net margin55.9%+35.7pp

FCF margin44.8%+16.8pp

Returns & leverage

See full

Return on equity17.1%+11.5pp

Debt / equity0×0.0×

Current ratio21.3×+16.0×

Where this comes from

Reported directly by Ligand Pharmaceuticals in its filing.

Tagged under the XBRL concept lgnd:FinancialRoyaltyAssetsGross.

The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ligand Pharmaceuticals's tolerance therapeutics (tzield®) — gross carrying value.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ligand Pharmaceuticals's tolerance therapeutics (tzield®) — gross carrying value?: Ligand Pharmaceuticals (LGND) reported tolerance therapeutics (tzield®) — gross carrying value of $25.16M in Q1 2026.
What does tolerance therapeutics (tzield®) — gross carrying value mean?: This metric represents the total historical cost or initial recognized value of the financial asset associated with the Tzield royalty stream before any adjustments for impairment or amortization. It reflects the gross investment basis in the underlying pharmaceutical product's future revenue rights. Investors use this to understand the scale of the company's capital commitment to this specific therapeutic asset.